The estimated Net Worth of Robert Gut is at least $3.46 Million dollars as of 13 June 2024. Robert Gut owns over 3,504 units of uniQure N.V stock worth over $241,583 and over the last 7 years he sold QURE stock worth over $1,271,613. In addition, he makes $1,949,450 as Executive Director at uniQure N.V.
Robert has made over 12 trades of the uniQure N.V stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,504 units of QURE stock worth $17,940 on 13 June 2024.
The largest trade he's ever made was exercising 26,875 units of uniQure N.V stock on 23 June 2020 worth over $1,051,350. On average, Robert trades about 2,606 units every 72 days since 2017. As of 13 June 2024 he still owns at least 44,165 units of uniQure N.V stock.
You can see the complete history of Robert Gut stock trades at the bottom of the page.
Dr. Robert Gut M.D. Ph.D. has been appointed as Executive Director of the Company effective 10/14/2020. Dr. Gut was originally elected to the Board as a non-executive director in June 2018 He resigned that position in August 2018 to take the position of Chief Medical Officer because under Dutch law our non-executive directors are not able to hold executive positions with the Company. Dr. Gut has more than 20 years of experience in the biopharmaceutical industry leading clinical development and medical affairs activities in hematology and other therapeutic areas. For the majority of his career, Dr. Gut served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc. (NYSE: NVO), where he headed the company’s U.S. Biopharm Medical organization with leading products in hemophilia, endocrinology and women’s health (NovoSeven®, Norditropin® and Vagifem®), totaling approximately $1.6 billion in U.S. revenue. Over his career, Dr. Gut’s contributions have helped achieve six FDA product approvals and three new product indications. Dr. Gut has supported the launch of nine new products, overseeing medical activities including medical science liaison team building and health economics and outcomes research. He has also served as a member of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management for the FDA’s Center for Drug Evaluation and Research. Dr. Gut was appointed the Chief Medical Officer of Versartis, Inc. in September 2017 and received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland. He attended numerous postgraduate programs at Wharton, Stanford and Harvard Business School.
As the Executive Director of uniQure N.V, the total compensation of Robert Gut at uniQure N.V is $1,949,450. There are 1 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of $4,719,960.
Robert Gut is 55, he's been the Executive Director of uniQure N.V since 2020. There are 7 older and 8 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
Robert's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos, and William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
uniQure N.V executives and other stock owners filed with the SEC include: